Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.73 (
urokinase-type plasminogen activator
)
10,685
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
beta-Tryptase, a product of the TPSAB1 and TPSB2 genes, is a trypsin-like serine protease that is a major and selective component of the secretory granules of all human mast cells, accounting for as much as 25% of cell protein. Once mast cells are activated,
beta-tryptase
is released along with histamine and heparin proteoglycan. beta-Tryptase is a unique enzyme with a homotetrameric structure in which active sites face into the central cavity of the four monomers, stabilized by heparin-proteoglycan. This structure makes
beta-tryptase
resistant to most biological inhibitors of serine proteases. Without stabilization, at neutral pH
beta-tryptase
converts to inactive monomers. Tryptase levels are elevated in bronchoalveolar lavage (BAL) fluid obtained from atopic asthmatics and in serum during systemic anaphylactic shock. Several synthetic small molecular weight
beta-tryptase
inhibitors reduced Ag-induced airway hypersensitivity in animals, suggesting that
beta-tryptase
is involved in the pathogenesis of airway inflammation. Although the major biologic substrate(s) of
beta-tryptase
remain ambiguous, the protease can digest several proteins of potential biologic importance, including fibrinogen, fibronectin, pro-
urokinase
, pro-matrix metalloprotease-3 (proMMP-3), protease activated receptor-2 (PAR2) and complement component C3. Recently, monomers of
beta-tryptase
with enzymatic activity have been detected in vitro. Here we discuss how
beta-tryptase
monomers with enzymatic activity were identified as well as their potential role in vivo.
...
PMID:Active monomers of human beta-tryptase have expanded substrate specificities. 1803 27